Circulating miR-21 as a potential biomarker in human digestive system carcinoma: a systematic review and diagnostic meta-analysis

References

• Aalami, A.H., et al., 2020a. MicroRNA‐223 in gastrointestinal cancers: a systematic review and diagnostic meta‐analysis. European journal of clinical investigation, e13448.
   PubMed Web of Science ®Google Scholar
• Aalami, A.H., Mesgari, M., and Sahebkar, A., 2020b. Synthesis and characterization of green zinc oxide nanoparticles with antiproliferative effects through apoptosis induction and MicroRNA modulation in breast cancer cells. Bioinorganic chemistry and applications, 2020, 8817110.
   PubMed Web of Science ®Google Scholar
• Abdi, E., et al., 2020. Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers. Expert review of molecular diagnostics, 20 (11), 1121–1138.
   PubMed Web of Science ®Google Scholar
• Arnold, M., et al., 2020. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology, 159 (1), 335–349.e15.
   PubMed Web of Science ®Google Scholar
• Bharali, D., et al., 2019. Expression analysis of MicroRNA-21 and MicroRNA-122 in hepatocellular carcinoma. Journal of clinical and experimental hepatology, 9 (3), 294–301.
   PubMed Web of Science ®Google Scholar
• Borenstein, M., Hedges, L., and Rothstein, H., 2007. Meta-analysis: fixed effect vs. random effects. meta-analysis.com
   Google Scholar
• Chen, D., et al., 2020. LncRNA growth arrest-specific transcript 5 targets miR-21 gene and regulates bladder cancer cell proliferation and apoptosis through PTEN. Cancer medicine, 9 (8), 2846–2858.
   PubMed Web of Science ®Google Scholar
• Dehghan, F., et al., 2019. miR-21: a promising biomarker for the early detection of colon cancer. OncoTargets and therapy, 12, 5601–5607.
   PubMed Web of Science ®Google Scholar
• Egger, M., et al., 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ (clinical research ed.), 315 (7109), 629–634.
   PubMed Web of Science ®Google Scholar
• Emami, S.S., et al., 2019. Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer. Journal of cancer research and therapeutics, 15 (1), 115–119.
   PubMed Web of Science ®Google Scholar
• Feng, Y., et al., 2020. The diagnostic value of miR-21 combined with CT in patients with liver cancer. Clinical and translational oncology.
   Web of Science ®Google Scholar
• Ferlay, J., et al., 2018. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer.
   Google Scholar
• Ferracin, M., Veronese, A., and Negrini, M., 2010. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert review of molecular diagnostics, 10 (3), 297–308.
   PubMed Web of Science ®Google Scholar
• Franck, M., et al., 2020. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World journal of hepatology, 12 (11), 1031–1045.
   PubMed Web of Science ®Google Scholar
• Goto, T., et al., 2018. An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. Bmc cancer, 18 (1), 116.
   PubMed Web of Science ®Google Scholar
• Grande, A.J., et al., 2014. Exercise for cancer cachexia in adults. Cochrane database of systematic reviews, CD010804.
   PubMed Web of Science ®Google Scholar
• Gu, Y., Fei, Z., and Zhu, R., 2020. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Anti-cancer drugs, 31 (4), 385–393.
   PubMed Web of Science ®Google Scholar
• Guo, X., et al., 2017. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget, 8 (27), 44050–44058.
   PubMedGoogle Scholar
• Hirata, Y., et al., 2014. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC cancer, 14, 799.
   PubMed Web of Science ®Google Scholar
• Huang, S.X., et al., 2020. Maspin inhibits MCF-7 cell invasion and proliferation by downregulating miR-21 and increasing the expression of its target genes. Oncology letters, 19 (4), 2621–2628.
   PubMed Web of Science ®Google Scholar
• Huang, Y., et al., 2018b. Serum microRNA panel excavated by machine learning as a potential biomarker for the detection of gastric cancer. Oncology reports, 39, 1338–1346.
   PubMed Web of Science ®Google Scholar
• Huang, Y., Yin, J., and Samawi, H., 2018a. Methods improving the estimate of diagnostic odds ratio. Communications in statistics - simulation and computation, 47 (2), 353–366.
   Web of Science ®Google Scholar
• Islami, F., et al., 2018. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA: a cancer journal for clinicians, 68 (1), 31–54.
   PubMed Web of Science ®Google Scholar
• Jones, C.M. and Athanasiou, T., 2005. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. The annals of thoracic surgery, 79 (1), 16–20.
   PubMed Web of Science ®Google Scholar
• Kalinina, T.S., et al., 2020. Association between lymph node status and expression levels of androgen receptor, miR-185, miR-205, and miR-21 in breast cancer subtypes. International journal of breast cancer, 2020, 3259393.
   PubMed Web of Science ®Google Scholar
• Kanaan, Z., et al., 2012. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Annals of surgery, 256 (3), 544–551.
   PubMed Web of Science ®Google Scholar
• Kangas, R., et al., 2014. Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy–a study with monozygotic twin pairs. Mechanisms of ageing and development, 143-144, 1–8.
   PubMed Web of Science ®Google Scholar
• Khalighfard, S., et al., 2018. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Scientific reports, 8 (1), 11.
   PubMed Web of Science ®Google Scholar
• Komatsu, S., et al., 2016. Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma. American journal of cancer research, 6, 1511.
   PubMed Web of Science ®Google Scholar
• Konno, M., et al., 2019. Distinct methylation levels of mature microRNAs in gastrointestinal cancers. Nature communications, 10 (1), 7.
   PubMed Web of Science ®Google Scholar
• Kurashige, J., et al., 2012. Serum microRNA‐21 is a novel biomarker in patients with esophageal squamous cell carcinoma. Journal of surgical oncology, 106 (2), 188–192.
   PubMed Web of Science ®Google Scholar
• Larner, A., 2015. The Q* index: a useful global measure of dementia screening test accuracy. Dementia and geriatric cognitive disorders extra, 5 (2), 265–270.
   PubMed Web of Science ®Google Scholar
• Le, H.-B., et al., 2012. Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and post-operative lung carcinoma patients. Medical oncology, 29 (5), 3190–3197.
   PubMed Web of Science ®Google Scholar
• Lee, A. and Kim, S.-N., 2020. Serum MicroRNA on inflammation: a literature review of mouse model studies. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 25 (7), 513–538.
   PubMed Web of Science ®Google Scholar
• Li, B-s., et al., 2012. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS, 7 (7), e41629.
   Web of Science ®Google Scholar
• Li, J., et al., 2020. Curcumin inhibits hepatocellular carcinoma via regulating miR-21/TIMP3 axis. Evidence-based complementary and alternative medicine : ECAM, 2020, 2892917.
   PubMed Web of Science ®Google Scholar
• Mayne, S.T., Playdon, M.C., and Rock, C.L., 2016. Diet, nutrition, and cancer: past, present and future. Nature reviews. Clinical oncology, 13 (8), 504–515.
   PubMed Web of Science ®Google Scholar
• Mohammadlou, M., et al., 2020. Apoptotic effect of berberine via Bcl‐2, ROR1, and mir‐21 in patients with B‐chronic lymphocytic leukemia. Phytotherapy research.
   PubMed Web of Science ®Google Scholar
• Moher, D., et al., PRISMA-P Group, 2015. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews, 4, 1.
   PubMed Web of Science ®Google Scholar
• Moriyama, T., et al., 2009. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular cancer therapeutics, 8 (5), 1067–1074.
   PubMed Web of Science ®Google Scholar
• Nedaeinia, R., et al., 2016. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer gene therapy, 23 (8), 246–253.
   PubMed Web of Science ®Google Scholar
• Negoi, I., et al., 2017. MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer – a systematic review and meta-analysis. American journal of surgery, 214 (3), 515–524.
   PubMed Web of Science ®Google Scholar
• Ni, K., et al., 2019. miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism. Cancer cell international, 19, 219.
   PubMed Web of Science ®Google Scholar
• O’Brien, S., et al., 2020. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Digestive diseases and sciences, 65 (9), 2611–2675.
   Web of Science ®Google Scholar
• Papagiannakopoulos, T., Shapiro, A., and Kosik, K.S., 2008. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer research, 68 (19), 8164–8172.
   PubMed Web of Science ®Google Scholar
• Sazanov, A.A., et al., 2017. Plasma and saliva miR-21 expression in colorectal cancer patients. Journal of applied genetics, 58 (2), 231–237.
   PubMed Web of Science ®Google Scholar
• Shen, Z., et al., 2020. miR-21 overexpression promotes esophageal squamous cell carcinoma invasion and migration by repressing tropomyosin 1. Gastroenterology research and practice, 2020, 6478653.
   PubMed Web of Science ®Google Scholar
• Song, M. and Giovannucci, E., 2016. Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA oncology, 2 (9), 1154–1161.
   PubMed Web of Science ®Google Scholar
• Toiyama, Y., et al., 2013. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. JNCI: Journal of the national cancer institute, 105 (12), 849–859.
   PubMedGoogle Scholar
• Tomimaru, Y., et al., 2012. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Journal of hepatology, 56 (1), 167–175.
   PubMed Web of Science ®Google Scholar
• Wan, T., Iyer, D.N., and Ng, L., 2020. Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer. Histology and histopathology, 35 (3), 225–237.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2009. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer prevention research, 2 (9), 807–813.
   PubMed Web of Science ®Google Scholar
• Wang, B. and Zhang, Q., 2012. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. Journal of cancer research and clinical oncology, 138 (10), 1659–1666.
   PubMed Web of Science ®Google Scholar
• Watson, J., et al., 2019. Blood markers for cancer. BMJ (clinical research ed.), 367, l5774.
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research, 2015. Diet, nutrition, physical activity, and liver cancer. Continuous Update Project Report.
   Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research, 2016. Diet, nutrition, physical activity, and stomach cancer. Continuous Update Project Report.
   Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research, 2018. Continuous Update Project Expert Report: diet, nutrition, physical activity and colorectal cancer.
   Google Scholar
• Wu, J., et al., 2015. MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 20 (1), 58–63.
   PubMed Web of Science ®Google Scholar
• Xu, J., et al., 2011. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular carcinogenesis, 50 (2), 136–142.
   PubMed Web of Science ®Google Scholar
• Xu, L.-H., et al., 2016. Blood-based circulating MicroRNAs are potential diagnostic biomarkers for leukemia: result from a meta-analysis Cellular. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38 (3), 939–949.
   PubMedGoogle Scholar
• Ye, M., et al., 2014. Diagnostic values of salivary versus and plasma microRNA-21 for early esophageal cancer Nan fang yi ke da xue xue bao=. Nan fang yi ke da xue xue bao = journal of Southern medical university, 34 (6), 885–889.
   PubMedGoogle Scholar
• Yin, C., et al., 2015. Potential role of circulating MiR-21 in the diagnosis and prognosis of digestive system cancer: a systematic review and meta-analysis. Medicine, 94 (50), e2123.
   PubMed Web of Science ®Google Scholar
• Zhao, M., et al., 2019. The regulatory role of non-coding RNAs on programmed cell death four in inflammation and cancer. Frontiers in oncology, 9, 919.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2020. The role of miR-21/RECK in the inhibition of osteosarcoma by curcumin. Molecular and cellular probes, 51, 101534.
   PubMed Web of Science ®Google Scholar
• Zhuang, C., et al., 2016. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 40 (4), 386–396.
   PubMed Web of Science ®Google Scholar
• Zhuang, H., et al., 2020. Exosome-encapsulated microRNA-21 from esophageal squamous cell carcinoma cells enhances angiogenesis of human umbilical venous endothelial cells by targeting SPRY1. Cancer management and research, 12, 10651–10667.
   PubMed Web of Science ®Google Scholar